Company Analysis
Sign in

Beam Therapeutics Inc. (BEAM)

Nasdaq: BEAM · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2018
Full chart Alerts Compare
Grade6.4
◀ Past 6.9● Present 6.6▶ Future 5.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

12 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Beam Therapeutics Inc.’s names, not what it holds today.

Patents granted
12
12 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 4 in 2024 and 2 in 2023
Applications published
87
21 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology8
Organic fine chemistry2
Pharmaceuticals1
Computer technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Beam Therapeutics Inc. its own name
US, as the owner printed on each patent. 14 more under the same name are not counted (printed in GB)
12 granted
42 published
Beam Therapeutics Inc. its own name
named as the applicant on its applications, in US
0 granted
45 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 28, 202512,454,694Compositions and methods for improving base editingBiotechnologyBeam Therapeutics Inc.
May 13, 202512,296,053Nanomaterials comprising triolsOrganic fine chemistryBeam Therapeutics Inc.
Apr 8, 202512,268,753Nanomaterials comprising a biodegradable featureOrganic fine chemistryBeam Therapeutics Inc.
Nov 5, 202412,133,884Methods of substituting pathogenic amino acids using programmable base editor systemsBiotechnologyBeam Therapeutics Inc.
Oct 22, 202412,125,145Systems and methods for implemented mixed reality in laboratory automationComputer technologyBeam Therapeutics Inc.
Aug 13, 202412,059,477NanomaterialsPharmaceuticalsBeam Therapeutics Inc.
Jun 25, 202412,016,908Compositions and methods for treating hemoglobinopathiesBiotechnologyBeam Therapeutics Inc.
Oct 24, 202311,795,443Uses of adenosine base editorsBiotechnologyBeam Therapeutics Inc.
Sep 12, 202311,752,202Compositions and methods for treating hemoglobinopathiesBiotechnologyBeam Therapeutics Inc.
May 31, 202211,344,609Compositions and methods for treating hemoglobinopathiesBiotechnologyBeam Therapeutics Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387509NANOMATERIALS COMPRISING A BIODEGRADABLE FEATUREPharmaceuticalsBeam Therapeutics Inc.
Nov 20, 20252025/0354138PRIME EDITING OF SINGLE BASE MUTATIONS IN ALPHA-1 ANTITRYPSIN DEFICIENCYBiotechnologyBeam Therapeutics Inc.
Oct 23, 20252025/0325702COMPOSITIONS AND METHODS FOR EDITING A TRANSTHYRETIN GENEPharmaceuticalsBeam Therapeutics Inc.
Oct 9, 20252025/0312491BASE EDITING OF TRANSTHYRETIN GENEBiotechnologyBeam Therapeutics Inc.
Sep 25, 20252025/0297287COMPOSITIONS AND METHODS FOR GENOME EDITING THE NEONATAL FC RECEPTORBiotechnologyBeam Therapeutics Inc.
Sep 18, 20252025/0288690RNA BASE EDITING COMPOSITIONS, SYSTEMS, METHODS AND USES THEREOFBiotechnologyBeam Therapeutics Inc.
Aug 21, 20252025/0262304FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAMEBiotechnologyBeam Therapeutics Inc.
Jul 24, 20252025/0236852LARGE SERINE RECOMBINASES, SYSTEMS AND USES THEREOFBiotechnologyBeam Therapeutics Inc.
Jul 10, 20252025/0223614SYNTHETIC POLYPEPTIDES AND USES THEREOFBiotechnologyBeam Therapeutics Inc.
Jul 10, 20252025/0223587COMPOSITIONS AND METHODS FOR TREATING A CONGENITAL EYE DISEASEPharmaceuticalsBeam Therapeutics Inc.
What it applied for, 2024 to 2025: Biotechnology 30 · Pharmaceuticals 11 · Organic fine chemistry 3 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BEAM · research, not advice